[Google Scholar] 54.Wang J, Lin C-Y, Moore C, Jhunjhunwala A and Jokerst JV, Langmuir, 2018, 34, 359365
Overall, these findings indicate that reductions in GPx3 abundance trends with disease severity with stage 1 having the highest mean levels of GPx3 (1.99 g/ml 0.73 g/ml) and the highest K1/U1 ratio (0.86), followed by the stage 2 with a mean of 1.2 g/ml 0.54 g/ml and average K2/U2 ratio of 0.67, with the most severe form of konzo, stage 3, displaying the largest reduction in average protein abundance (mean: 1.15 g/ml 0.58 g/ml) and the lowest K3/U3 ratio of 0.59 (Supplementary Data 1)
[Epub ahead of print])
Log 2 -transformed relative expression values and Ct values were imported for mRNA and miRNA statistical analysis, respectively
To ensure adequate statistical power, a priori power analysis was conducted using G*Power software (version 3.1) based on previously observed effect sizes from pilot studies and similar experimental models in the literature
CJC-1295 with DAC Dosing For the long-acting CJC-1295 with DAC variant (completely different from no DAC): Research Dose: 30-60mcg per kilogram of body weight Frequency: Once or twice weekly (due to extended half-life) Example: A 90kg (200lb) person = 2,700-5,400mcg per injection Duration: Ongoing with medical monitoring Source: PubMed Clinical Study - "Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg" Important: This is a clinical research dose for CJC-1295 WITH DAC
